IBDEI030 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,861,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,862,0)
 ;;=L98.9^^3^32^31
 ;;^UTILITY(U,$J,358.3,862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,862,1,3,0)
 ;;=3^Disorder of the skin and subcutaneous tissue, unspecified
 ;;^UTILITY(U,$J,358.3,862,1,4,0)
 ;;=4^L98.9
 ;;^UTILITY(U,$J,358.3,862,2)
 ;;=^5009595
 ;;^UTILITY(U,$J,358.3,863,0)
 ;;=M34.9^^3^32^143
 ;;^UTILITY(U,$J,358.3,863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,863,1,3,0)
 ;;=3^Systemic sclerosis, unspecified
 ;;^UTILITY(U,$J,358.3,863,1,4,0)
 ;;=4^M34.9
 ;;^UTILITY(U,$J,358.3,863,2)
 ;;=^5011785
 ;;^UTILITY(U,$J,358.3,864,0)
 ;;=M34.0^^3^32^127
 ;;^UTILITY(U,$J,358.3,864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,864,1,3,0)
 ;;=3^Progressive systemic sclerosis
 ;;^UTILITY(U,$J,358.3,864,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,864,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,865,0)
 ;;=M34.1^^3^32^10
 ;;^UTILITY(U,$J,358.3,865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,865,1,3,0)
 ;;=3^CR(E)ST syndrome
 ;;^UTILITY(U,$J,358.3,865,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,865,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,866,0)
 ;;=R21.^^3^32^133
 ;;^UTILITY(U,$J,358.3,866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,866,1,3,0)
 ;;=3^Rash and other nonspecific skin eruption
 ;;^UTILITY(U,$J,358.3,866,1,4,0)
 ;;=4^R21.
 ;;^UTILITY(U,$J,358.3,866,2)
 ;;=^5019283
 ;;^UTILITY(U,$J,358.3,867,0)
 ;;=R23.3^^3^32^141
 ;;^UTILITY(U,$J,358.3,867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,867,1,3,0)
 ;;=3^Spontaneous ecchymoses
 ;;^UTILITY(U,$J,358.3,867,1,4,0)
 ;;=4^R23.3
 ;;^UTILITY(U,$J,358.3,867,2)
 ;;=^5019295
 ;;^UTILITY(U,$J,358.3,868,0)
 ;;=I96.^^3^32^44
 ;;^UTILITY(U,$J,358.3,868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,868,1,3,0)
 ;;=3^Gangrene, not elsewhere classified
 ;;^UTILITY(U,$J,358.3,868,1,4,0)
 ;;=4^I96.
 ;;^UTILITY(U,$J,358.3,868,2)
 ;;=^5008081
 ;;^UTILITY(U,$J,358.3,869,0)
 ;;=E11.21^^3^33^13
 ;;^UTILITY(U,$J,358.3,869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,869,1,3,0)
 ;;=3^Type 2 diab w diabetic nephropathy
 ;;^UTILITY(U,$J,358.3,869,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,869,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,870,0)
 ;;=E10.21^^3^33^1
 ;;^UTILITY(U,$J,358.3,870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,870,1,3,0)
 ;;=3^Type 1 diab w diabetic nephropathy
 ;;^UTILITY(U,$J,358.3,870,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,870,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,871,0)
 ;;=E11.321^^3^33^19
 ;;^UTILITY(U,$J,358.3,871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,871,1,3,0)
 ;;=3^Type 2 diab w mild nonprlf diabetic rtnop w macular edema
 ;;^UTILITY(U,$J,358.3,871,1,4,0)
 ;;=4^E11.321
 ;;^UTILITY(U,$J,358.3,871,2)
 ;;=^5002634
 ;;^UTILITY(U,$J,358.3,872,0)
 ;;=E11.329^^3^33^20
 ;;^UTILITY(U,$J,358.3,872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,872,1,3,0)
 ;;=3^Type 2 diab w mild nonprlf diabetic rtnop w/o macular edema
 ;;^UTILITY(U,$J,358.3,872,1,4,0)
 ;;=4^E11.329
 ;;^UTILITY(U,$J,358.3,872,2)
 ;;=^5002635
 ;;^UTILITY(U,$J,358.3,873,0)
 ;;=E11.331^^3^33^21
 ;;^UTILITY(U,$J,358.3,873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,873,1,3,0)
 ;;=3^Type 2 diab w moderate nonprlf diab rtnop w macular edema
 ;;^UTILITY(U,$J,358.3,873,1,4,0)
 ;;=4^E11.331
 ;;^UTILITY(U,$J,358.3,873,2)
 ;;=^5002636
 ;;^UTILITY(U,$J,358.3,874,0)
 ;;=E11.339^^3^33^22
 ;;^UTILITY(U,$J,358.3,874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,874,1,3,0)
 ;;=3^Type 2 diab w moderate nonprlf diab rtnop w/o macular edema
 ;;^UTILITY(U,$J,358.3,874,1,4,0)
 ;;=4^E11.339
 ;;^UTILITY(U,$J,358.3,874,2)
 ;;=^5002637
 ;;
 ;;$END ROU IBDEI030
